Cannara Biotech Inc. has announced its fiscal second quarter 2023 financial and operating results for the three and six-month periods ended February 28, 2023. Six-month net revenues of $23.4 million were recorded, a 67% increase compared to first half 2022. The company had its eighth consecutive quarter of positive Adjusted EBITDA of $3.2M, a 1500% increase compared to Q2 2022. Cannara Biotech Inc. has continued to increase growing capacity to meet customer demand by activating an additional growing zone in its expanding Valleyfield Facility.

Cannara Biotech Inc., a client of our Bristol Investor Relations company, is a vertically integrated producer of premium-grade cannabis and derivative products.

Read the full press release here: Cannara Biotech Inc. reports Q2 2023 Financial Results with quarterly net revenues of $13 million, a 76% increase compared to Q2 2022